NASDAQ:FLGT Fulgent Genetics Q2 2026 Earnings Report $21.02 -0.37 (-1.73%) Closing price 04:00 PM EasternExtended Trading$21.16 +0.14 (+0.66%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Fulgent Genetics EPS ResultsActual EPSN/AConsensus EPS -$0.46Beat/MissN/AOne Year Ago EPSN/AFulgent Genetics Revenue ResultsActual RevenueN/AExpected Revenue$94.00 millionBeat/MissN/AYoY Revenue GrowthN/AFulgent Genetics Announcement DetailsQuarterQ2 2026Date7/31/2026TimeBefore Market OpensConference Call DateFriday, July 31, 2026Conference Call Time8:30AM ETConference Call ResourcesEarnings HistoryCompany Profile Fulgent Genetics Earnings HeadlinesHead-To-Head Survey: CareCloud (NASDAQ:CCLD) and Fulgent Genetics (NASDAQ:FLGT)July 7 at 10:23 AM | americanbankingnews.comFulgent Genetics (FLGT) Stock Faces Mixed Analyst Target Changes After Margin QuestionsJune 25, 2026 | finance.yahoo.comDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in could be a costly mistake. He calls it among the most overhyped, overvalued large-cap offerings ever pushed onto everyday investors. Tilson believes a rare economic event is approaching - one with serious consequences for your portfolio this summer. He has prepared a free analysis outlining what he sees and the specific steps he recommends taking now.July 7 at 1:00 AM | Stansberry Research (Ad)How The Fulgent Genetics (FLGT) Investment Story Is Evolving With Recent DevelopmentsJune 8, 2026 | finance.yahoo.comLowey Dannenberg, P.C. is Investigating Fulgent Genetics Inc. (NASDAQ: FLGT) for Potential Violations of the Federal Securities Laws and Encourages Investors to Contact the FirmMay 22, 2026 | financialpost.comFLowey Dannenberg, P.C. is Investigating Fulgent Genetics Inc. (NASDAQ: FLGT) for Potential Violations of the Federal Securities Laws and Encourages Investors to Contact the FirmMay 22, 2026 | globenewswire.comSee More Fulgent Genetics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Fulgent Genetics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Fulgent Genetics and other key companies, straight to your email. Email Address About Fulgent GeneticsFulgent Genetics (NASDAQ:FLGT) (NASDAQ: FLGT) is a California-based company specializing in high-complexity genetic testing and diagnostic services. Operating from its headquarters in Temple City, Fulgent leverages next-generation sequencing (NGS) technologies and advanced bioinformatics to deliver a broad range of clinical and research assays. The company’s infrastructure includes CAP- and CLIA-certified laboratories, enabling it to process large volumes of samples with rapid turnaround times. Fulgent’s product portfolio encompasses hereditary cancer panels, rare disease and neuromuscular disorder testing, pharmacogenomic screenings, non-invasive prenatal tests, and infectious disease assays including COVID-19 diagnostics. The company offers both clinician-ordered and direct-to-consumer testing models, as well as custom research services for biopharmaceutical partners and academic institutions. Through proprietary automation and AI-driven analytical pipelines, Fulgent aims to maintain cost-effective operations and high data quality for clients across the United States and select international markets. Founded in 2011 by Ming Hsieh, Fulgent Genetics completed its initial public offering in 2019, expanding its capacity and geographic reach. Under the leadership of founder and chairman Ming Hsieh and an experienced management team, the company continues to invest in laboratory automation, informatics enhancements and strategic partnerships. Fulgent remains committed to regulatory compliance, quality assurance and ongoing innovation in molecular diagnostics to support personalized medicine and population health initiatives.View Fulgent Genetics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles GE Vernova’s Power Surge Turns the Grid Into an AI Trade2 Short Squeezes for Summer Speculation: What the Bears Are Getting WrongBig Beautiful Boycott: Can It Really Hurt Coca-Cola, Amazon, and Kraft Heinz Stocks?Contrarian Alert: 5 Downgraded Stocks That May Reward Long-Term InvestorsMarketBeat Week in Review – 06/29 - 07/03Meta’s AI Compute Push Could Turn Its Massive CapEx Bill Into a Competitive WeaponVisa’s Open USD Push Puts Circle’s Stablecoin Moat Under Pressure Upcoming Earnings PepsiCo (7/9/2026)Delta Air Lines (7/9/2026)Bank of America (7/14/2026)The Goldman Sachs Group (7/14/2026)JPMorgan Chase & Co. (7/14/2026)Wells Fargo & Company (7/14/2026)Citigroup (7/14/2026)Fastenal (7/14/2026)Cintas (7/15/2026)ASML (7/15/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
